British HIV association guidelines for prescribing antiretroviral therapy in pregnancy (1998)

Sexually Transmitted Infections

Volumn 75, Issue 2, 1999, Pages 90-97

  Taylor, Graham P ^a   Lyall, E G Hermione ^a   Mercey, Danielle ^a   Smith, Richard ^a   Chester, Tracey ^a   Newell, Marie Louise ^a   Tudor Williams, Gareth ^a  

^a NONE

Author keywords

Antiretroviral therapy; BHIVA; Guidelines; Pregnancy; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LYMPHOCYTE COUNT; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RASH; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 0032962436     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.75.2.90     Document Type: Article

References (55)

1. 1 Unlinked Anonymous Surveys Steering Group. Unlinked Anonymous HIV Prevalence Monitoring Programme, England and Wales. London: Department of Health, December 1996.
2. 2 BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for anti-retroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
3. 3 Gazzard B, Moyle G on behalf of the BHIVA Guidelines Writing Committee. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-16.
4. 4 Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
5. 5 Anti-retroviral Pregnancy Registry for didanosine, indinavir, lamivudine, saquinavir, stavudine, zalcitabine, zidovudine. Interim Report, 1 January 1989 through 31 December 1997. A collaborative project managed by Bristol Myers Squibb Co, Glaxo Wellcome, Hoffman-La Roche, Inc, and Merck & Co Inc, Research Triangle Park, NC 1997.
6. 6 O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993;168:1510-6.
7. 7 Paediatric AIDS Clinical Trials Group Protocol 185 Executive Summary. National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD; 1997 March 25; presented at a conference on global strategies for the prevention of HIV transmission from mothers to infants; Washington, DC, September 3-6 1997.
8. 8 Dabis, F, Méda N, Msellati P, et al. Zidovudine to decrease mother-to-child transmission of HIV-1: A Phase II study in West Africa, 1995-1996 (ANRS 049A). Abstract TuC 444, XIth International Conference on AIDS; Vancouver, 7-12 July 1996.
9. 9 Vuthipongse P, Bhadrakom C, Chaisilwattana P, et al. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR 1998;47:151-4.
10. 10 Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine (ZDV) regimen utilised in the AIDS Clinical Trials Group 076 Protocol. [Abstract] A conference on global strategies for the prevention of HIV transmission from mothers to infants; Washington, DC, September 3-6 1997.
11. 11 Ayers KM, Clive D, Tucker WE Jr, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 1996;32:148-58.
12. 12 Olivero OA, Anderson LM, Diwan BA, et al. AZT is a genotoxic transplacental carcinogen in animal models. J Acquir Immune Defic Syndr 1997;14:A29 [Abstract 52]
13. 13 Moodley J, Moodley d, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327-33.
14. 14 Eriksen N, Helfgott A, Doyle M. Combination antiretroviral therapy for the treatment of HIV infection in pregnant women: safety profiles in women and newborns. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 February 1-5; Chicago, IL, 1998 [Abstract 235].
15. 15 Patil SD, Livingston E, McKinney RE, et al and the ACTG 249 team. Does pregnancy affect the pharmocokinetics of didanosine (ddI) in HIV-1 infected women? Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 February 1-5; Chicago, IL, 199S [Abstract 225].
16. 16 Livingston E, Patil SD, Unadkat JD, et al and the ACTG 249 team. Placental transfer of didanosine (ddI) and initial evaluation of didanosine toxicity in HIV-1 infected pregnant women and their offspring. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 February 1-5; Chicago, IL, 1998 [Abstract 226].
17. 17 Mirochnick M, Fenton T, Gagnier P, et al for the Pediatric Aids Clinical Trials Group Protocol 250 Team. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their newborns. J Infect Dis 1998;178:368-74.
18. 18 Jungmann E, Mohan D, Mercey D, at al. Outcome of HIV-1 positive pregnancies in London since the introduction of the ACTG 076 Protocol: a retrospective analysis. 4th International Congress on Drug Therapy in HIV Infection Glasgow; 1998 Nov 8-12; [P313A] In AIDS 1998; 12(suppl 4):S96.
19. 19 Lorenzi P, Masserei V, Laubereau B, et al. Safety of combined anti-retroviral therapies with or without protease inhibitors in pregnant HIV-infected women and their offspring. Conference Supplement, 12th World AIDS Conference Geneva; 1998 June 28-July 3 [Abstract 32453].
20. 20 Sperling RS, Shapiro DS, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of HIV-1 from mother to infant. N Engl J Med 1996;335: 1621-9.
21. 21 Cooper ER, Nugent KP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174: 1207-11.
22. 22 Mayaux M-J, Teglas J-P, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr 1997;131:857-62.
23. 23 Gibb DM, MacDonagh SE, Tookey PA, et al. Uptake of interventions to reduce mother-to-child transmission of HIV in the United Kingdom and Ireland. AIDS 1997;11: F53-8.
24. 24 Lyall EGH, Stainsby C, Taylor GP, et al. Review of the uptake of interventions to prevent mother to child transmission of HIV by women aware of their HIV status. BMJ 1998;316:268-70.
25. 25 Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl Med 1987; 317:192-7.
26. 26 Concorde Coordinating Committee. MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
27. 27 Centers for Disease Control. Case control study of HIV seroconversion in health care workers after percutaneous exposures to HIV-infected blood: France, UK and US, Jan '88-Aug '94. MMWR 1995;44:607-60.
28. 28 Birkhead GS, Warren BL, Charbonneau TT, et al. Evidence for intermediate rates of perinatal HIV transmission with partial 076 regimens: results of an observational study. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 February 1-5; Chicago, IL, 1998 [Abstract 244].
29. 29 Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-52.
30. 30 Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother to child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis 1997;175:172-5.
31. 31 Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS 1997;11:437-44.
32. 32 Rasheed S, Li Z, Xu d, et al. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1996;175:122-9.
33. 33 Contopoulos-Ioannidis DG, Ioannidis JPA. Maternal cell-free viraemia in the natural history of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:126-35.
34. 34 O'Shea S, Newell M-L, Dunn DT, et al. Maternal viral load, CD4 count and vertical transmission of HIV-1. J Med Virol 1998;54:113-17.
35. 35 Coovadia HM, Moodley D, Moodley J, et al. Viral load and perinatal transmission in HIV-1 infected black South African women and their infants given lamivudine (3TC) alone or in combination with zidovudine (AZT) [NUCB 2018]. A conference on global strategies for the prevention of HIV transmission from mothers to infants; 1997 September 3-6; Washington, DC [Abstract].
36. 36 Clarke JR, Braganza R, Ait-Khaled M, et al. Rapid development of the M184V mutation in women receiving zidovudine and lamivudine during pregnancy. [Abstract 131-W9] 3rd European Conference on Experimental AIDS Research (ECEAR); 1998 Feb 28-Mar 3; Munich, 1998.
37. 37 Schuurman R, Nijhuis M, van-Leeuwen LM, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-19.
38. 38 Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
39. 39 Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
40. 40 Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 1996;335: 1081-90.
41. 41 Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
42. 42 Brun-Vézinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997;350:983-90.
43. 43 Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998;279;1984-91.
44. 44 Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-33.
45. 45 Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
46. 46 Rouzioux C, Costagliola D, Burgard M, et al and the HIV infection in newborns French Collaborative Study Group. Estimating timing of transmission of mother-to-child HIV-1 transmission by use of a Markov model. Am J Epidemiol 1995;142:1330-7.
47. 47 Duliege AM, Amos CL Felton S, B et al. Birth order, delivery route, and concordance in the transmission of HIV-1 from mothers to twins. J Pediatr 1995;126:625-32.
48. 48 Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission, interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.
49. 49 Semprini AE. An international randomised trial of mode of delivery in HIV infected women. Abstracts of the 12th World AIDS Conference; 1999 June 28-July 3; Geneva, 1998 [Abstract 23599].
50. 50 Read J. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies (the International Perinatal HIV Group). Abstracts of the 12th World AIDS Conference; 1998 June 28-July 3; Geneva, 1998 [Abstract 23275].
51. 51 de Jong MD, de Boer RJ, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of anti-retroviral treatment. AIDS 1997;11:F79-84.
52. 52 Imrie A, Beveridge A, Genn W, V et al and the Sydney Primary HIV Infection Study Group. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis 1997;175:1502-6.
53. 53 Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-11.
54. 54 Colgrove RC, Pitt J, Chung PH, et al. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998;12:2281-8.
55. 55 Eastman PS, Shapiro DE, Coombs RW, et al. Maternal genotypic ZDV resistance and failure of ZDV to prevent mother-child HIV-1 transmission. Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; 1997 January 22-26; Washington, DC, 1997:160 [Abstract 516].